We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Receives EMA Approval for Additional Eye Drug Use
Novartis Receives EMA Approval for Additional Eye Drug Use
European regulators approved Novartis’ eye drop drug Travatan to treat pediatric glaucoma patients, expanding patent protection for the treatment by another six months.